Kernal Biologics Announces \$25 Million Series A Financing to Advance its Oncology mRNA

Client News July 7, 2022

Gunderson Dettmer represented client Kernal Biologics, a Massachusetts-based biotech company, in its \$25 million Series A financing led by Hummingbird Ventures with participation from Amgen Ventures. Kernal aims to develop mRNA beyond COVID 19 and vaccines and focus on treating cancer patients with as few side effects as possible. The new capital will be used to expand the mRNA platform and advance the filing of application that will alow to start testing immune-oncology candidate in humans.

In the announcement of the transaction, Co-founder and CEO of Kernal Biologics Yusuf Erkul said, "There's a major unmet need to improve outcomes for cancer patients and Kernal Bio has built a strong rational for the use of its novel mRNA technology in cancer therapeutics. This financing further validates that rational. Our breakthrough onco-selective mRNA approach can enable specific protein expression in malignant cells, widening the therapeutic window of mRNAs in oncology."

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Jen Lichtman and Ali Blum.

Companies: Kernal Biologics Hummingbird Ventures

Related People



Timothy H. Ehrlich PARTNER P +1 617 648 9399

Related Services

Early-Stage Company Seed, Venture and Growth Financings

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad